Clinical trials: Anthracyclines
Triple Negative Breast Cancer
NeoCARD: Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients
This is a single-arm Phase II study to assess the efficacy of a 12-18 week neoadjuvant carboplatin, paclitaxel, and pembrolizumab (CPP) regimen in a response-adaptive manner for triple-negative breast cancer (TNBC) patients who…
- Trial name
- NeoCARD (NCT06845319)
- Testing
- Carboplatin, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Medical University of South Carolina
Breast Carcinoma, Breast Lump
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
This randomized phase II trial studies how well carboplatin and paclitaxel with or without panitumumab work in treating patients with invasive triple negative breast cancer.
- Conditions
- Breast Carcinoma, Breast Lump, Edema, Erythema
- Trial name
- NCT02876107
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Childhood Cancers
Cardiovascular Function in Adult Survivors of Childhood Malignancies
Anthracyclines have been used commonly to treat children with solid tumours and haematological malignancies and have led to their increased survival. Nonetheless, anthracycline has the side effect of cardiotoxicity.
- Trial name
- NCT01415999
- Where
- China
- Volunteers
- 142 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Breast Cancer
Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer
The purpose of this study is to compare the pathological complete response (pCR) rate in triple-negative or Her2 positive breast cancer patients treated with neoadjuvant docetaxel, anthracycline and cyclophosphamide (TAC) or…
- Trial name
- NATT (NCT00912444)
- Testing
- Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide, Docetaxel, cyclophosphamide
- Where
- 27 sites in China
- Volunteers
- 102 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Sarcoma
Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy such as soblidotin use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00064220
- Testing
- soblidotin
- Where
- 6 sites in United States, Puerto Rico
- Sponsor
- Daiichi Sankyo
Metastases, Brain
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.
- Trial name
- NCT00820222
- Testing
- capecitabine, lapatinib, trastuzumab
- Where
- 164 sites in United States, Belgium and 12 more
- Volunteers
- 540 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma Cancer, Breast Cancer
Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity
This study is a single center, phase 1 clinical imaging study designed to assess the role of 68Ga-Galmydar Positron Emission Tomography (PET) imaging for detection of cardiotoxicity in human subjects with breast cancer or…
- Conditions
- Lymphoma Cancer, Breast Cancer, Cancer of the Breast, Non-Hodgkin Lymphoma
- Trial name
- NCT07838649
- Testing
- 68Ga-Galmydar, PET/MRI, 18F-FDG
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Washington University School of Medicine
Metastatic Breast Cancer, Recurrent Breast Cancer
VEGF Trap in Treating Patients With Metastatic Breast Cancer
This phase II trial is studying how well VEGF Trap works in treating patients with metastatic breast cancer. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor
- Conditions
- Metastatic Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00369655
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer
Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant
The purpose of this study is to determine the response rates for Ixabepilone (BMS-247550) in subjects with metastatic breast cancer previously treated with an anthracycline and who are taxane resistant.
- Trial name
- NCT01019577
- Testing
- Ixabepilone
- Volunteers
- 54 people
- Sponsor
- R-Pharm
Breast Cancer
5-Fluorouracil Combined With CoFactor (5-10 Methylenetetrahydrofolate) in Treating Advanced Breast Cancer Patients
A multi-center, open-label, single-arm Phase II trial assessing the efficacy and safety of weekly bolus infusions of 5-fluorouracil combined with CoFactor (5-10 methylenetetrahydrofolate) in advanced breast cancer patients who…
- Trial name
- NCT00434369
- Testing
- CoFactor (ANX-510)
- Where
- 6 sites in Argentina, Mexico and 3 more
- Volunteers
- 31 people
- Sponsor
- Mast Therapeutics, Inc.
Cancer
Effects of Carvedilol on Cardiotoxicity in Cancer Patients Submitted to Anthracycline Therapy
Neoplasia is the main cause of general death in the Brazilian population. In 2016, they were responsible for approximately 211,343 (16%) deaths, followed by cardiovascular diseases (12.6%).
- Trial name
- CardioTox (NCT04939883)
- Testing
- Carvedilol
- Where
- Brazil
- Volunteers
- 1,018 people
- Sponsor
- Hospital Sirio-Libanes
Breast Neoplasms, Adjuvant
Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer
Anthracycline based regimens followed by a taxane (CALGB-9344 trial and NSABP-B28) or reversed (MD Anderson Adjuvant Trial) has already accepted as adjuvant therapy for node positive breast cancer.
- Conditions
- Breast Neoplasms, Adjuvant, Chemotherapy
- Trial name
- NCT00525642
- Testing
- Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide
- Where
- 5 sites in China
- Volunteers
- 603 people
- Sponsor
- Fudan University
Breast Cancer
Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer
This trial will evaluate the effectiveness of standard adjuvant treatment with CMF chemotherapy versus treatment with weekly docetaxel in patients with high-risk breast cancer who are 65 years of age and older or are poor…
- Trial name
- NCT00193011
- Testing
- Docetaxel, Cyclophosphamide, Methotrexate
- Volunteers
- 150 people
- Sponsor
- SCRI Development Innovations, LLC
Chemotherapy-induced Nausea and Vomiting
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intravenous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion…
- Trial name
- NCT03403712
- Testing
- fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
- Where
- 40 sites in United States, Georgia
- Volunteers
- 404 people
- Sponsor
- Helsinn Healthcare SA
Acute Myelogenous Leukemia, Myelodysplastic Syndromes
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS
The purpose of this trial is to to determine the safety and effectiveness of therapeutic combination - Clofarabine and Cytarabine for the treatment of AML and MDS.
- Conditions
- Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
- Trial name
- NCT00334074
- Testing
- Clofarabine and Cytarabine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Baylor Research Institute
Emesis
Aprepitant in the Prevention of Delayed Emesis Induced by Cyclophosphamide Plus Anthracyclines in Breast Cancer Patients
The aim of the study is to compare efficacy and tolerability of aprepitant versus dexamethasone in the prevention of delayed emesis induced by moderately emetogenic chemotherapy (cyclophosphamide plus anthracyclines) in breast…
- Trial name
- NCT00869973
- Testing
- Aprepitant, dexamethasone
- Where
- Italy
- Volunteers
- 580 people
- Sponsor
- S. Maria Hospital, Terni
Breast Cancer
Irinotecan for Advanced and Metastatic Breast Cancer
This trial aims to evaluate the safety and efficacy of third-line or later irinotecan treatment for locally recurrent or metastatic breast cancer among Chinese patients who have received at least two regimens containing…
- Trial name
- NCT03562390
- Testing
- Irinotecan
- Where
- China
- Volunteers
- 124 people
- Sponsor
- Liaoning Cancer Hospital & Institute
Nodal T-follicular Helper Cell Lymphoma
Golidocitinib Plus Anthracycline-based Therapy for Untreated Nodal T-follicular Helper (TFH) Cell Lymphoma
This is a prospective, multicenter, open-label, single-arm, phase II clinical study to evaluate the safety and efficacy of golidocitinib in combination with an anthracycline-based regimen as first-line treatment for patients with…
- Trial name
- NCT07753642
- Testing
- Golidocitinib, Doxorubicin, Epirubicin
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Sun Yat-sen University
Breast Cancer
Maintenance Chemotherapy in Metastatic Breast Cancer
This is a randomized, prospective and multicenter phase III study. Two-hundred-sixty-two (262) patients on each arm will be recruited in the study.
- Trial name
- NCT00289263
- Testing
- Paclitaxel
- Where
- 7 sites in Italy
- Volunteers
- 524 people
- Sponsor
- MANTA 1 Study Italian Collaborative Group
Breast Cancer
Mathematical Modeling to Predict Response to Neoadjuvant Chemotherapy in Breast Cancer
This is a feasibility study evaluating the use of a mathematical model to predict response to standard neoadjuvant anthracycline / taxane based chemotherapy in patients with breast cancer.
- Trial name
- NCT03983538
- Testing
- Mathematical modeling to predict response to chemotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- New Mexico Cancer Research Alliance